The Effects of a Pressure-Enabled Drug Delivery (PEDD™) Microcatheter on Radiotracer Distribution Compared to a Standard Microcatheter in Radioembolization, an Interim Analysis
… Hepatic Arterial Infusion of the Class C TLR9 Agonist SD-101 in Pressure-Enabled Regional Immuno-Oncology (PERIO) Phase 1 Trials for Liver Tumors with authors.
… Pancreatic Retrograde Venous Infusion (PRVI) Significantly Enhances Delivery of NearIR Labelled SD-101 TLR9 Agonist to Targeted Regions of the Porcine Pancreas.
… Pressure-Enabled Intravascular Delivery (PEDD™) of SD-101 Into the Liver with Systemic or Subcutaneous Checkpoint Inhibitor for Control of Liver Metastases in a Murine Model
… Pressure-Enabled Drug Delivery (PEDD™) of a Class C TLR9 Agonist in Combination with Checkpoint Inhibitor Therapy in a Murine Pancreatic Cancer Model
… Enhanced Delivery of a TLR9 Type C Agonist SD-101 to Liver Tumors in the Oncopig using Pressure Enabled Drug Delivery (PEDD™) Versus a Standard Endhole Catheter
… Improved Delivery of a TLR-9 Agonist to Liver Tissue by Intravascular Pressure-Enabled Drug Delivery (PEDD™) Compared with Direct Needle Injection
… Regional Infusion of a Class C TLR9 Agonist Enhances Liver Tumor Microenvironment Reprogramming and MDSC Reduction to Improve Responsiveness to Systemic Checkpoint Inhibition
… Comparison of Pancreatic Tissue Uptake of Oxaliplatin Delivered by Systemic Circulation and by Pancreatic Retrograde Venous Infusion (PRVI)
… Abstract No. 158628: PERIO-01: Enabling Tumor Microenvironment Reprogramming by a TLR9 Agonist Using Pressure-Enabled Drug Delivery™ (PEDD™) to Address Intrahepatic Immunosuppression and Drug Delivery Barriers
…